Molecular aspects of the RT/drug interactions. Perspective of dual inhibitors

Current Pharmaceutical Design

Volumn 19, Issue 10, 2013, Pages 1850-1859

  Distinto, Simona ^a   Maccioni, Elias ^a   Meleddu, Rita ^a   Corona, Angela ^a   Alcaro, Stefano ^b   Tramontano, Enzo ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

HIV; RT binding pockets and novel inhibitors

Indexed keywords

ABACAVIR; ADEFOVIR; CP 94707; DAPIVIRINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RIBONUCLEASE H; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

DNA SYNTHESIS; DRUG APPROVAL; DRUG BINDING; DRUG TARGETING; ENZYME ACTIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROPHOBICITY; PERIPHERAL NEUROPATHY; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION;

DRUG RESISTANCE, VIRAL; HIV-1; MODELS, MOLECULAR; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H;

EID: 84876709287     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319100009     Document Type: Review

References (73)

1. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a Tlymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220(4599): 868-71.
2. Schupbach J, Popovic M, Gilden RV, Gonda MA, Sarngadharan MG, Gallo RC. Serological analysis of a subgroup of human Tlymphotropic retroviruses (HTLV-III) associated with AIDS. Science 1984; 224(4648): 503-5.
3. www.unaids.org/en/media/unaids/contentassets/documents/ unaidspublication/ 2011/JC2216_WorldAIDSday_report_2011_en.pdf.
4. Mehellou Y, De Clercq E. Twenty-six years of anti-HIV drug discovery: Where do we stand and where do we go? J Med Chem 2009; 53(2): 521-38.
5. Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust 2007; 186(3): 146-51.
6. Ratner L, Haseltine W, Patarca R, et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985; 313(6000): 277-84.
7. Hughes S, Arnold E, Hostomsky Z. RNase H of retroviral reverse transcriptases. In: H CR, Toulmé JJ., Eds. Ribonucleases. Les Editions Inserm: Paris; 1998; pp. 195-224.
8. Huber HE, Richardson CC. Processing of the primer for plus strand DNA synthesis by human immunodeficiency virus 1 reverse transcriptase. J Biol Chem 1990; 265(18): 10565-73.
9. Rausch JW, Le Grice SFJ. 'Binding, bending and bonding': polypurine tract-primed initiation of plus-strand DNA synthesis in human immunodeficiency virus. Int J Biochem Cell Biol 2004; 36(9): 1752-66.
10. Basu VP, Song M, Gao L, Rigby ST, Hanson MN, Bambara RA. Strand transfer events during HIV-1 reverse transcription. Virus Res 2008; 134(1-2): 19-38.
11. Divita G, Rittinger K, Geourjon C, Deléage G, Goody RS. Dimerization kinetics of HIV-1 and HIV-2 Reverse Transcriptase: A two step process. J Mol Biol 1995; 245(5): 508-21.
12. Jacobo-Molina A, Ding J, Nanni RG, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci USA 1993; 90(13): 6320-4.
13. Kohlstaedt L, Wang J, Friedman J, Rice P, Steitz T. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256(5065): 1783-90.
14. Liu S, Abbondanzieri EA, Rausch JW, Grice SFJL, Zhuang X. Slide into action: Dynamic shuttling of HIV Reverse Transcriptase on nucleic acid substrates. Science 2008; 322(5904): 1092-7.
15. Steitz TA. Structural biology: A mechanism for all polymerases. Nature 1998; 391(6664): 231-2.
16. Dash C, Scarth BJ, Badorrek C, Götte M, Le Grice SFJ. Examining the ribonuclease H primer grip of HIV-1 reverse transcriptase by charge neutralization of RNA/DNA hybrids. Nucleic Acids Res 2008; 36(20): 6363-71.
17. Sarafianos SG, Marchand B, Das K, et al. Structure and function of HIV-1 Reverse Transcriptase: Molecular mechanisms of polymerization and Inhibition. J Mol Biol 2009; 385(3): 693-713.
18. Kellinger MW, Johnson KA. Nucleotide-dependent conformational change governs specificity and analog discrimination by HIV reverse transcriptase. Proc Natl Acad Sci USA 2010; 107(17): 7734-9.
19. Tramontano E, Di Santo R. HIV-1 RT-associated RNase H function inhibitors: Recent advances in drug development. Curr Med Chem 2010; 17(26): 2837-53.
20. Nowotny M, Gaidamakov SA, Crouch RJ, Yang W. Crystal structures of RNase H bound to an RNA/DNA hybrid: Substrate specificity and metal-dependent catalysis. Cell 2005; 121(7): 1005-16.
21. Telesnitsky A, Goff S. Reverse transcriptase and the generation of retroviral DNA. In: Coffin JM HS, Varmus HE., Eds. Retroviruses. Cold Spring Harbor Laboratory Press: NY; 1997; pp. 121-60.
22. Grohmann D, Godet J, Mély Y, Darlix J-L, Restle T. HIV-1 nucleocapsid traps Reverse Transcriptase on nucleic acid substrates. Biochemistry 2008; 47(46): 12230-40.
23. Ji X, Klarmann GJ, Preston BD. Effect of Human Immunodeficiency Virus Type 1 (HIV-1) nucleocapsid protein on HIV-1 reverse transcriptase activity in vitro. Biochemistry 1996; 35(1): 132-43.
24. Meyer PR, Matsuura SE, So AG, Scott WA. Unblocking of chainterminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci USA 1998; 95(23): 13471-6.
25. Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA. Phenotypic mechanism of HIV-1 resistance to 3'-Azido-3'-deoxythymidine (AZT):β increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral Reverse Transcriptase. Biochemistry 1998; 37(45): 15908-17.
26. Aguiar RS, Peterlin BM. APOBEC3 proteins and reverse transcription. Virus Res 2008; 134(1-2): 74-85.
27. Cihlar T, Chen MS. Incorporation of selected nucleoside phosphonates and anti-human immunodeficiency virus nucleotide analogues into DNA by human DNA polymerases β, α and ć. Antivir Chem Chemother 1997; 8(3): 187-95.
28. Das K, Martinez SE, Bauman JD, Arnold E. HIV-1 reverse transcriptase complex with DNA and nevirapine reveals nonnucleoside inhibition mechanism. Nat Struct Mol Biol 2012; 19(2): 253-9.
29. Hachiya A, Kodama EN, Sarafianos SG, et al. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol 2008; 82(7): 3261-70.
30. Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, Mellors JW. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3 '-azido-3 '-dideoxythymidine. J Virol 2007; 81(15): 7852-9.
31. Delviks-Frankenberry KA, Nikolenko GN, Barr R, Pathak VK. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3-Azido-3'-deoxythymidine resistance. J Virol 2007; 81(13): 6837-45.
32. Yap SH, Sheen CW, Fahey J, et al. N348I in the connection domain of HIV-1 Reverse Transcriptase confers Zidovudine and Nevirapine resistance. PLoS Med 2007; 4(12): e335.
33. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, et al. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3 '-azido-3 '-deoxythymidine resistance. Proc Natl Acad Sci USA 2007; 104(1): 317-22.
34. Balzarini J, Naesens L, Aquaro S, et al. Intracellular metabolism of CycloSaligenyl 3 '-azido-2 ',3 '-dideoxythymidine monophosphate, a prodrug of 3 '-azido-2 ',3 '-dideoxythymidine (zidovudine). Mol Pharmacol 1999; 56(6): 1354-61.
35. Cihlar T, Ray AS. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antivir Res 2010; 85(1): 39-58.
36. Ehteshami M, Scarth BJ, Tchesnokov EP, et al. Mutations M184V and Y115F in HIV-1 Reverse Transcriptase discriminate against "Nucleotide-competing Reverse Transcriptase inhibitors". J Biol Chem 2008; 283(44): 29904-11.
37. Jochmans D, Deval J, Kesteleyn B, et al. Indolopyridones inhibit Human Immunodeficiency Virus Reverse Transcriptase with a novel mechanism of action. J Virol 2006; 80(24): 12283-92.
38. Freisz S, Bec G, Radi M, et al. Crystal structure of HIV-1 Reverse Transcriptase bound to a non-nucleoside inhibitor with a novel mechanism of action. Angew Chem, Int Ed 2010; 49(10): 1805-8.
39. Huang HF, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-I reverse transcriptase: Implications for drug resistance. Science 1998; 282(5394): 1669-75.
40. Sluis-Cremer N, Tachedjian G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res 2008; 134(1-2): 147-56.
41. Zhan P, Chen X, Li D, Fang Z, De Clercq E, Liu X. HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev 2011DOI: 10.1002/med.20241.
42. Das K, Lewi PJ, Hughes SH, Arnold E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of nonnucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 2005; 88(2): 209-31.
43. Zhan P, Liu X, Li Z, Pannecouque C, De Clercq E. Design strategies of novel NNRTIs to overcome drug resistance. Curr Med Chem 2009; 16(29): 3903-17.
44. Sahlberg C, Zhou X-X. Development of non-nucleoside Reverse Transcriptase inhibitors for anti-HIV therapy. Anti-Infect Agents Med Chem 2008; 7(2): 101-17.
45. Ding JP, Das K, Moereels H, et al. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol 1995; 2(5): 407-15.
46. Das K, Bauman JD, Rim AS, et al. Crystal structure of tert-Butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in Complex with HIV-1 Reverse Transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket. J Med Chem 2011; 54(8): 2727-37.
47. Halgren TA. Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 2009; 49(2): 377-89.
48. Lindberg J, Sigursson S, Löwgren S, et al. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur J Biochem 2002; 269(6): 1670-7.
49. Das K, Clark AD, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (Etravirine) and related non-nucleoside Reverse Transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004; 47(10): 2550-60.
50. Pata JD, Stirtan WG, Goldstein SW, Steitz TA. Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 2004; 101(29): 10548-53.
51. Das K, Ding J, Hsiou Y, et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J Mol Biol 1996; 264(5): 1085-100.
52. Camarasa M-J, Velazquez S, San-Felix A, Perez-Perez M-J. TSAO derivatives the first non-peptide inhibitors of HIV-1 RT dimerization. Antivir Chem Chemother 2005; 16(3): 147-53.
53. Hsiou Y, Ding J, Das K, Clark JAD, Hughes SH, Arnold E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 å resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 1996; 4(7): 853-60.
54. Pelemans H, Esnouf R, De Clercq E, Balzarini J. Mutational analysis of Trp-229 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors. Mol Pharmacol 2000; 57(5): 954-60.
55. Lu X, Liu L, Zhang X, et al. F18, a novel small-molecule nonnucleoside Reverse Transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis. Antimicrob Agents Chemother 2012; 56(1): 341-51.
56. Tramontano E. HIV-1 RNase H: Recent progress in an exciting, yet little explored, drug target. Mini-Rev Med Chem 2006; 6(6): 727-37.
57. Klumpp K, Mirzadegan T. Recent progress in the design of small molecule inhibitors of HIV RNase H. Curr Pharm Des 2006; 12(15): 1909-22.
58. Himmel DM, Maegley KA, Pauly TA, et al. Structure of HIV-1 Reverse Transcriptase with the inhibitor β-Thujaplicinol bound at the RNase H active site. Structure 2009; 17(12): 1625-35.
59. Chung S, Himmel DM, Jiang J-K, et al. Synthesis, activity, and structural analysis of novel α-Hydroxytropolone inhibitors of Human Immunodeficiency Virus Reverse Transcriptase-associated Ribonuclease H. J Med Chem 2011; 54(13): 4462-73.
60. Kirschberg TA, Balakrishnan M, Squires NH, et al. RNase H active site inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase: Design, biochemical activity, and structural information. J Med Chem 2009; 52(19): 5781-4.
61. Lansdon EB, Liu Q, Leavitt SA, et al. Structural and binding analysis of pyrimidinol carboxylic acid and N-hydroxy quinazolinedione HIV-1 RNase H inhibitors. Antimicrob Agents Chemother 2011; 55(6): 2905-15.
62. Hang JQ, Rajendran S, Yang Y, et al. Activity of the isolated HIV RNase H domain and specific inhibition by N-hydroxyimides. Biochem Biophys Res Commun 2004; 317(2): 321-9.
63. Tramontano E, Esposito F, Badas R, Di Santo R, Costi R, La Colla P. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antivir Res 2005; 65(2): 117-24.
64. Artico M, Massa S, Mai A, Marongiu ME, Piras G, Tramontano E, Lacolla P. 3,4-Dihydro-2-Alkoxy-6-Benzyl-4-Oxopyrimidines (DABOs)-A new class of specific inhibitors of Human-Immunodeficiency-Virus type-1. Antivir Chem Chemother 1993; 4(6): 361-8.
65. Himmel DM, Sarafianos SG, Dharmasena S, et al. HIV-1 Reverse Transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone Bound at a novel site. ACS Chem Biol 2006; 1(11): 702-12.
66. Su H-P, Yan Y, Prasad GS, et al. Structural basis for the inhibition of RNase H activity of HIV-1 Reverse Transcriptase by RNase H active site-directed inhibitors. J Virol 2010; 84(15): 7625-33.
67. Wendeler M, Lee H-F, Bermingham A, et al. Vinylogous ureas as a novel class of inhibitors of Reverse Transcriptase-associated ribonuclease H activity. ACS Chem Biol 2008; 3(10): 635-44.
68. Felts AK, LaBarge K, Bauman JD, et al. Identification of alternative binding sites for inhibitors of HIV-1 Ribonuclease H through comparative analysis of virtual enrichment studies. J Chem Inf Model 2011; 51(8): 1986-98.
69. Sluis-Cremer N, Arion D, Parniak MA. Destabilization of the HIV-1 Reverse Transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol Pharmacol 2002; 62(2): 398-405.
70. Esposito F, Kharlamova T, Distinto S, et al. Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases. FEBS J 2011; 278(9): 1444-57.
71. Distinto S, Esposito F, Kirchmair J, et al. Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2Dfingerprint-and pharmacophore-based virtual screening approach. Eur J Med Chem 2012; 50(0): 216-29.
72. Ortuso F, Langer T, Alcaro S. GBPM: GRID-based pharmacophore model: concept and application studies to protein-protein recognition. Bioinformatics 2006; 22(12): 1449-55.
73. SiteMap. Schrodinger Suite, 2010, Portland, OR.